These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 34184561)

  • 1. Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
    Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?
    El Gharib K; Lilly E; Chebel R
    Immunotherapy; 2021 Sep; 13(13):1105-1111. PubMed ID: 34184569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future directions of the use of novel immunotherapeutic agents in bladder cancer.
    Lenfant L; Aminsharifi A; Seisen T; Rouprêt M
    Curr Opin Urol; 2020 May; 30(3):428-440. PubMed ID: 32141936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoints inhibitors in the management of high-risk non-muscle-invasive bladder cancer. A scoping review.
    García-Perdomo HA; Sánchez AL; Spiess PE
    Urol Oncol; 2022 Sep; 40(9):409.e1-409.e8. PubMed ID: 35232680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for urothelial carcinoma: Metastatic disease and beyond.
    Poon DM
    Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():18-23. PubMed ID: 32852900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.
    Nadal R; Apolo AB; Girardi DM; Hahn NM; Bellmunt J
    Urol Oncol; 2023 Jan; 41(1):27-34. PubMed ID: 34756410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibition in upper tract urothelial carcinoma.
    Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
    World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of immunotherapy in bladder cancer.
    Rhea LP; Mendez-Marti S; Kim D; Aragon-Ching JB
    Cancer Treat Res Commun; 2021; 26():100296. PubMed ID: 33421822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
    Meeks JJ; Black PC; Galsky M; Grivas P; Hahn NM; Hussain SA; Milowsky MI; Steinberg GD; Svatek RS; Rosenberg JE
    Eur Urol; 2023 Nov; 84(5):473-483. PubMed ID: 37258363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
    Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
    Int J Clin Oncol; 2024 Aug; 29(8):1096-1104. PubMed ID: 38850448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
    Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
    J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving systemic management of urothelial cancers.
    Tan WS; Tan MY; Alhalabi O; Campbell MT; Kamat AM; Gao J
    Curr Opin Oncol; 2023 May; 35(3):186-199. PubMed ID: 36966497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.